4-Quinolone Derivatives: High-Affinity Ligands at the Benzodiazepine Site of Brain GABAAReceptors. Synthesis, Pharmacology, and Pharmacophore Modeling
Citations Over Time
Abstract
The 3-ethoxycarbonyl-4-quinolone compound 1 has previously been identified via a database search as an interesting lead compound for ligand binding at the benzodiazepine site of GABA(A) receptors (Kahnberg et al. J. Mol. Graphics Modelling 2004, 23, 253-261). Pharmacophore-guided optimization of this lead compound yielded a number of high-affinity ligands for the benzodiazepine site including compounds 20 and 23-25 displaying sub-nanomolar affinities. A few of the compounds have been tested on the alpha(1)beta(2)gamma(2S) and alpha(3)beta(2)gamma(2S) GABA(A) receptor subtypes, and two of the compounds (5 and 19) display selectivity for alpha(1)- versus alpha(3)-containing receptors by a factor of 22 and 27, respectively. This selectivity for alpha(1)beta(2)gamma(2S) is in the same range as that for the well-known alpha(1) subunit selective compound zolpidem.
Related Papers
- → Pharmacological profile of benzodiazepine site ligands with recombinant GABAA receptor subtypes(1996)51 cited
- → Differences in pharmacological profiles of a new generation of benzodiazepine and non-benzodiazepine hypnotics(1990)93 cited
- → Role of gamma-aminobutyric acid type A (GABAA) receptor subtypes in acute benzodiazepine physical dependence-like effects: evidence from squirrel monkeys responding under a schedule of food presentation(2013)19 cited
- → The use of a pharmacophore model for identification of novel ligands for the benzodiazepine binding site of the GABAA receptor(2004)34 cited
- → Substituted 3-(2-benzoxazyl)-benzimidazol-2-(1H)-ones: A new class of GABAA brain receptor ligands(2000)11 cited